PPARγ signaling exacerbates mammary gland tumor development

Genes and Development

Volumn 18, Issue 5, 2004, Pages 528-540

  Saez, Enrique ^a,d   Rosenfeld, John ^a,e   Livolsi, Antonia ^b   Olson, Peter ^c   Lombardo, Eleuterio ^a   Nelson, Michael ^a   Banayo, Ester ^a   Cardiff, Robert D ^b   Izpisua Belmonte, Juan Carlos ^a   Evans, Ronald M ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^e Nippon Chemi Con   (Japan)

Author keywords

Breast cancer; Mammary tumors; Nuclear receptor; PPAR ; Wnt signaling

Indexed keywords

COMPLEMENTARY DNA; GREEN FLUORESCENT PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMID DNA; RNA; WNT PROTEIN;

ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST TUMOR; EMBRYO; FEMALE; GENE EXPRESSION; IN SITU HYBRIDIZATION; MAMMARY GLAND; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSGENIC ANIMAL; ZEBRA FISH;

ANIMALS; CELL DIFFERENTIATION; CHICKENS; GENES, REPORTER; HERPES SIMPLEX VIRUS PROTEIN VMW65; LIGANDS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; WNT PROTEINS; ZEBRAFISH; ZEBRAFISH PROTEINS;

ANIMALIA; DANIO RERIO; MUS MUSCULUS;

EID: 12144287188     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.1167804     Document Type: Article

References (71)

1. Abe, A., Kiriyama, Y., Hirano, M., Miura, T., Kamiya, H., Harashima, H., and Tokumitsu, Y. 2002. Troglitazone suppresses cell growth of KU812 cells independently of PPARγ. Eur. J. Pharmacol. 436: 7-13.
2. Akiyama, T.E., Nicol, C.J., and Gonzalez, F.J. 2001. On par with PPARs. Trends Genet. 17: 310-312.
3. Barak, Y., Nelson, M.C., Ong, E.S., Jones, Y.Z., Ruiz-Lozano, P., Chien, K.R., Koder, A., and Evans, R.M. 1999. PPARγ is required for placental, cardiac, and adipose tissue development. Mol. Cell 4: 585-595.
4. Bienz, M. and Clevers, H. 2000. Linking colorectal cancer to Wnt signaling. Cell 103: 311-320.
5. Brantley, D.M., Chen, C.L., Muraoka, R.S., Bushdid, P.B., Bradberry, J.L., Kittrell, F., Medina, D., Matrisian, L.M., Kerr, L.D., and Yull, F.E. 2001. Nuclear factor-κB (NF-κB) regulates proliferation and branching in mouse mammary epithelium. Mol. Biol. Cell 12: 1445-1455.
6. Burstein, H.J., Demetri, G.D., Mueller, E., Sarraf, P., Spiegelman, B.M., and Winer, E.P. 2003. Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: A phase II study. Breast Cancer Res. Treat. 79: 391-397.
7. Castrillo, A., Mojena, M., Hortelano, S., and Bosca, L. 2001. Peroxisome proliferator-activated receptor-γ-independent inhibition of macrophage activation by the non-thiazolidinedione agonist L-796,449. Comparison with the effects of 15-deoxy-delta(12,14)-prostaglandin J(2). J. Biol. Chem. 276: 34082-34088.
8. Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., and Evans, R.M. 2001. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7: 48-52.
9. Clay, C.E., Namen, A.M., Atsumi, G., Trimboli, A.J., Fonteh, A.N., High, K.P., and Chilton, F.H. 2001. Magnitude of peroxisome proliferator-activated receptor-γ activation is associated with important and seemingly opposite biological responses in breast cancer cells. J. Investig. Med. 49: 413-420.
10. 2-induced apoptosis does not require PPARγ in breast cancer cells. J. Lipid Res. 43: 1818-1828.
11. Cogswell, P.C., Guttridge, D.C., Funkhouser, W.K., and Baldwin Jr., A.S. 2000. Selective activation of NF-κ B subunits in human breast cancer: Potential roles for NF-κ B2/p52 and for Bcl-3. Oncogene 19: 1123-1131.
12. Collett, G.P., Betts, A.M., Johnson, M.I., Pulimood, A.B., Cook, S., Neal, D.E., and Robson, C.N. 2000. Peroxisome proliferator-activated receptor α is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. Clin. Cancer Res. 6: 3241-3248.
13. Corton, J.C., Lapinskas, P.J., and Gonzalez, F.J. 2000. Central role of PPARα in the mechanism of action of hepatocarcinogenic peroxisome proliferators. Mutat. Res. 448: 139-151.
14. Cui, Y., Miyoshi, K., Claudio, E., Siebenlist, U.K., Gonzalez, F.J., Flaws, J., Wagner, K.U., and Hennighausen, L. 2002. Loss of the peroxisome proliferation-activated receptor γ (PPARγ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J. Biol. Chem. 277: 17830-17835.
15. Debrock, G., Vanhentenrijk, V., Sciot, R., Debiec-Rychter, M., Oyen, R., and Van Oosterom, A. 2003. A phase II trial with rosiglitazone in liposarcoma patients. Brit. J. of Cancer 89: 1409-1412.
16. Demetri, G.D., Fletcher, C.D., Mueller, E., Sarraf, P., Naujoks, R., Campbell, N., Spiegelman, B.M., and Singer, S. 1999. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci. 96: 3951-3956.
17. Detrich, H.W., Westerfield, M., Zon, L.I., and American Society for Cell Biology. 1999a. The Zebrafish: Biology. Academic Press, San Diego, CA.
18. -. 1999b. The Zebrafish: Genetics and genomics. Academic Press, San Diego, CA.
19. DuBois, R.N., Gupta, R., Brockman, J., Reddy, B.S., Krakow, S.L., and Lazar, M.A. 1998. The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers. Carcinogenesis 19: 49-53.
20. Elstner, E., Muller, C., Koshizuka, K., Williamson, E.A., Park, D., Asou, H., Shintaku, P., Said, J.W., Heber, D., and Koeffler, H.P. 1998. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. 95: 8806-8811.
21. Foekens, J.A., Kos, J., Peters, H.A., Krasovec, M., Look, M.P., Cimerman, N., Meijer-van Gelder, M.E., Henzen-Logmans, S.C., van Putten, W.L., and Klijn, J.G. 1998. Prognostic significance of cathepsins B and L in primary human breast cancer. J. Clin. Oncol. 16: 1013-1021.
22. Gimble, J.M., Pighetti, G.M., Lerner, M.R., Wu, X., Lightfoot, S.A., Brackett, D.J., Darcy, K., and Hollingsworth, A.B. 1998. Expression of peroxisome proliferator activated receptor mRNA in normal and tumorigenic rodent mammary glands. Biochem. Biophys. Res. Commun. 253: 813-817.
23. Girnun, G.D., Smith, W.M., Drori, S., Sarraf, P., Mueller, E., Eng, C., Nambiar, P., Rosenberg, D.W., Bronson, R.T., Edelmann, W., et al. 2002. APC-dependent suppression of colon carcinogenesis by PPARγ. Proc. Natl. Acad. Sci. 99: 13771-13776.
24. Glover, H.R., Brewster, C.E., and Dilworth, S.M. 1999. Association between src-kinases and the polyoma virus oncogene middle T-antigen requires PP2A and a specific sequence motif. Oncogene 18: 4364-4370.
25. Gupta, R.A., Tan, J., Krause, W.F., Geraci, M.W., Willson, T.M., Dey, S.K., and DuBois, R.N. 2000. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer. Proc. Natl. Acad. Sci. 97: 13275-13280.
26. Guy, C.T., Cardiff, R.D., and Muller, W.J. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12: 954-961.
27. Hanahan, D. and Weinberg, R.A. 2000. The hallmarks of cancer. Cell 100: 57-70.
28. Harbeck, N., Alt, U., Berger, U., Kates, R., Kruger, A., Thomssen, C., Janicke, F., Graeff, H., and Schmitt, M. 2000. Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer. Int. J. Biol. Markers 15: 79-83.
29. He, T.C., Chan, T.A., Vogelstein, B., and Kinzler, K.W. 1999. PPARd is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335-345.
30. Ikezoe, T., Miller, C.W., Kawano, S., Heaney, A., Williamson, E.A., Hisatake, J., Green, E., Hofmann, W., Taguchi, H., and Koeffler, H.P. 2001. Mutational analysis of the peroxisome proliferator-activated receptor γ gene in human malignancies. Cancer Res. 61: 5307-5310.
31. Jaeckel, E.C., Raja, S., Tan, J., Das, S.K., Dey, S.K., Girod, D.A., Tsue, T.T., and Sanford, T.R. 2001. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor δ with head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 127: 1253-1259.
32. Kelly, G.M., Greenstein, P., Erezyilmaz, D.F., and Moon, R.T. 1995. Zebrafish wnt8 and wnt8b share a common activity but are involved in distinct developmental pathways. Development 121: 1787-1799.
33. Kinzler, K.W. and Vogelstein, B. 1996. Lessons from hereditary colorectal cancer. Cell 87: 159-170.
34. Knudson, A.G. 2001. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 1: 157-162.
35. Kubota, T., Koshizuka, K., Williamson, E.A., Asou, H., Said, J.W., Holden, S., Miyoshi, I., and Koeffler, H.P. 1998. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 58: 3344-3352.
36. Lefebvre, A.M., Chen, L, Desreumaux, P., Najib, J., Fruchart, J.C., Geboes, K., Briggs, M., Heyman, R., and Auwerx, J. 1998. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat. Med. 4: 1053-1057.
37. Memisoglu, A., Hankinson, S.E., Manson, J.E., Colditz, G.A., and Hunter, D.J. 2002. Lack of association of the codon 12 polymorphism of the peroxisome proliferator-activated receptor γ gene with breast cancer and body mass. Pharmacogenetics 12: 597-603.
38. Moore, K.J., Rosen, E.D., Fitzgerald, M.L., Randow, F., Andersson, L.P., Altshuler, D., Milstone, D.S., Mortensen, R.M., Spiegelman, B.M., and Freeman, M.W. 2001. The role of PPAR-γ in macrophage differentiation and cholesterol uptake. Nat. Med. 7: 41-47.
39. Mueller, E., Sarraf, P., Tontonoz, P., Evans, R.M., Martin, K.J., Zhang, M., Fletcher, C., Singer, S., and Spiegelman, B.M. 1998. Terminal differentiation of human breast cancer through PPAR γ. Mol. Cell 1: 465-470.
40. Mueller, E., Smith, M., Sarraf, P., Kroll, T., Aiyer, A., Kaufman, D.S., Oh, W., Demetri, G., Figg, W.D., Zhou, X.P., et al. 2000. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc. Natl. Acad. Sci. 97: 10990-10995.
41. Nusse, R. and Varmus, H.E. 1982. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31: 99-109.
42. Nwankwo, J.O. and Robbins, M.E. 2001. Peroxisome proliferator-activated receptor-γ expression in human malignant and normal brain, breast and prostate-derived cells. Prostaglandins Leukot. Essent. Fatty Acids 64: 241-245.
43. Olson, D.J., and Gibo, D.M. 1998. Antisense wnt-5a mimics wnt-1-mediated C57MG mammary epithelial transformation. Exp. Cell Res. 241: 134-141.
44. Palakurthi, S.S., Aktas, H., Grubissich, L.M., Mortensen, R.M., and Halperin, J.A. 2001. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res. 61: 6213-6218.
45. Pallas, D.C., Shahrik, L.K., Martin, B.L., Jaspers, S., Miller, T.B., Brautigan, D.L., and Roberts, T.M. 1990. Polyoma small and middle T antigens and SV40 small t antigenform stable complexes with protein phosphatase 2A. Cell 60: 167-176.
46. Paltoo, D., Woodson, K., Taylor, P., Albanes, D., Virtamo, J., and Tangrea, J. 2003. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ (PPAR-γ) gene and risk of prostate cancer among men in a large cancer prevention study. Cancer Lett. 191: 67-74.
47. Park, B.H., Vogelstein, B., and Kinzler, K.W. 2001. Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells. Proc. Natl. Acad. Sci. 98: 2598-2603.
48. Pierce Jr., D.F., Gorska, A.E., Chytil, A., Meise, K.S., Page, D.L., Coffey Jr., R.J., and Moses, H.L. 1995. Mammary tumor suppression by transforming growth factor β 1 transgene expression. Proc. Natl. Acad. Sci. 92: 4254-4258.
49. Pighetti, G.M., Novosad, W., Nicholson, C., Hitt, D.C., Hansens, C., Hollingsworth, A.B., Lerner, M.L., Brackett, D., Lightfoot, S.A., and Gimble, J.M. 2001. Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands. Anticancer Res. 21: 825-829.
50. Place, A.E., Suh, N., Williams, C.R., Risingsong, R., Honda, T., Honda, Y., Gribble, G.W., Leesnitzer, L.M., Stimmel, J.B., Willson, T.M., et al. 2003. The novel synthetic triterpenoid, CDDO-imidazole, inhibits inflammatory response and tumor growth in vivo. Clin. Cancer Res. 9: 2798-2806.
51. Polakis, P. 2000. Wnt signaling and cancer. Genes & Dev. 14: 1837-1851.
52. Ratcliffe, M.J., Itoh, K., and Sokol, S.Y. 2000. A positive role for the PP2A catalytic subunit in Wnt signal transduction. J. Biol. Chem. 275: 35680-35683.
53. Rayet, B. and Gelinas, C. 1999. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18: 6938-6947.
54. Roberts-Thomson, S.J. and Snyderwine, E.G. 2000. Characterization of peroxisome proliferator-activated receptor α in normal rat mammary gland and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced mammary gland tumors from rats fed high and low fat diets. Toxicol. Lett. 118: 79-86.
55. Rosen, E.D. and Spiegelman, B.M. 2001. PPARγ: A nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276: 37731-37734.
56. Rosenfeld, J.M., Vargas, R., Xie, W., and Evans, R.M. 2003. Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor Pregnane X Receptor. Mol. Endocr. 17: 1268-1282.
57. Saez, E., Tontonoz, P., Nelson, M.C., Alvarez, J.G., Ming, U.T., Baird, S.M., Thomazy, V.A., and Evans, R.M. 1998. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat. Med. 4: 1058-1061.
58. Sarraf, P., Mueller, E., Jones, D., King, F.J., DeAngelo, D.J., Partridge, J.B., Holden, S.A., Chen, L.B., Singer, S., Fletcher, C., et al. 1998. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat. Med. 4: 1046-1052.
59. Sarraf, P., Mueller, E., Smith, W.M., Wright, H.M., Kum, J.B., Aaltonen, L.A., de la Chapelle, A., Spiegelman, B.M., and Eng, C. 1999. Loss-of-function mutations in PPAR γ associated with human colon cancer. Mol. Cell 3: 799-804.
60. Schulte-Merker, S., Hammerschmidt, M., Beuchle, D., Cho, K.W., De Robertis, E.M., and Nusslein-Volhard, C. 1994a. Expression of zebrafish goosecoid and no tail gene products in wild-type and mutant no tail embryos. Development 120: 843-852.
61. Schulte-Merker, S., van Eeden, F.J., Halpern, M.E., Kimmel, C.B., and Nusslein-Volhard, C. 1994b. no tail (ntl) is the zebrafish homologue of the mouse T (Brachyury) gene. Development 120: 1009-1015.
62. Seagroves, T.N., Krnacik, S., Raught, B., Gay, J., Burgess-Beusse, B., Darlington, G.J., and Rosen, J.M. 1998. C/EBPβ, but not C/EBPα, is essential for ductal morphogenesis, lobuloalveolar proliferation, and functional differentiation in the mouse mammary gland. Genes & Dev. 12: 1917-1928.
63. Seed, B. 1998. PPARγ and colorectal carcinoma: Conflicts in a nuclear family. Nat. Med. 4: 1004-1005.
64. Sporn, M.B., Suh, N., and Mangelsdorf, D.J. 2001. Prospects for prevention and treatment of cancer with selective PPARγ modulators (SPARMs). Trends Mol. Med. 7: 395-400.
65. Suh, N., Wang, Y., Williams, C.R., Risingsong, R., Gilmer, T., Willson, T.M., and Sporn, M.B. 1999. A new ligand for the peroxisome proliferator-activated receptor-γ (PPAR-γ), GW7845, inhibits rat mammary carcinogenesis. Cancer Res. 59: 5671-5673.
66. Taipale, J. and Beachy, P.A. 2001. The Hedgehog and Wnt signalling pathways in cancer. Nature 411: 349-354.
67. Tontonoz, P., Singer, S., Forman, B.M., Sarraf, P., Fletcher, J.A., Fletcher, C.D., Brun, R.P., Mueller, E., Altiok, S., Oppenheim, H., et al. 1997. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc. Natl. Acad. Sci. 94: 237-241.
68. Walczak, R. and Tontonoz, P. 2002. PPARadigms and PPARadoxes. Expanding roles for PPARγ in the control of lipid metabolism. J. Lipid Res. 43: 177-186.
69. Wasan, H.S., Novelli, M., Bee, J., and Bodmer, W.F. 1997. Dietary fat influences on polyp phenotype in multiple intestinal neoplasia mice. Proc. Natl. Acad. Sci. 94: 3308-3313.
70. Willson, T.M., Brown, P.J., Sternbach, D.D., and Henke, B.R. 2000. The PPARs: From orphan receptors to drug discovery. J. Med. Chem. 43: 527-550.
71. Zimmet, P., Alberti, K.G., and Shaw, J. 2001. Global and societal implications of the diabetes epidemic. Nature 414: 782-787.